Mammalian Cell Culture Seed Expansion Patents: Leaders & Trends 2026
- Filings are concentrated but not locked up. the top 5 assignees hold 24.6% of all 2,644 records in scope, and the top 10 hold 36.7% — leaving a long tail of single- and few-filing entrants.
- The three-year trend is down, not flat. filings fell from 79 in 2021 to 45 in 2024, a 43% drop, after peaking at 105 in 2018.
- Bioreactor and testing claims are thinner than the biology. C12M (bioreactors) sits at 14.7% and G01N (material analysis) at 14.4% of records, well below the 97.3% claimed under core cell-engineering class C12N.
Filing growth compares 2021 (79 records) with 2024 (45) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 2,644 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
Seed expansion — the inoculum train that carries a cell line from vial thaw through the seeding densities and passage numbers needed to inoculate a production bioreactor — sits at the operational core of biologics manufacturing. This landscape covers 2,644 published records filed against seeding density, passage number, viability threshold, doubling time, inoculum train and culture transition concepts within mammalian, animal and CHO cell culture, classified under C12N, C12M and C12Q. The window runs from 2015 through the 2026-07-31 data cut-off.
Because publication lags filing by roughly 18 months, the most recent one to two years in any trend line are undercounts, not a genuine drop-off. The 2021-to-2024 comparison is the most recent span in this dataset that can be read as complete.
Filing trends and technology composition
Two views of the same 2,644 records: how filing volume has moved year over year, and how those records distribute across the IPC subclasses that define the technology.
Filing trend, 2017–2026
Filings peaked at 105 in 2018 and have declined since, falling from 79 in 2021 to 45 in 2024 — a 43% drop over that span. 2025 and 2026 figures are still filling in due to publication lag and should not be read as a continued slide.
IPC subclass composition
C12N (microorganisms and genetic engineering) covers 97.3% of records, confirming this is fundamentally a cell-engineering field. Downstream process classes — C12M bioreactors at 14.7% and G01N analytical methods at 14.4% — carry meaningfully fewer filings than the upstream biology, one signal of where claim density is lighter.
Shares are the percentage of the 2,644 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Mammalian Cell Culture Seed Expansion with Eureka
This page is one run against one query. Ask Eureka your own question about mammalian cell culture seed expansion and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative and most-cited filings
US8663945B2 — Methods of producing anti-TNF-alpha antibodies in mammalian cell culture
The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture.Assigned to AbbVie Inc., published 2014-03-04.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | EP0307247A2 | A method for culturing recombinant cells | 733 |
| 2 | WO2001051616A2 | Techniques for growth and differentiation of human pluripotent stem cells | 621 |
| 3 | US6642048B2 | Conditioned media for propagating human pluripotent stem cells | 438 |
| 4 | US5633162A | Method for culturing Chinese hamster ovary cells | 420 |
| 5 | US20020072117A1 | Human feeder cells that support proliferation of undifferentiated pluripotent stem cells | 397 |
| 6 | WO1999011764A2 | Methods for generating high titer helper-free preparations of recombinant AAV vectors | 385 |
| 7 | US5908782A | Chemically defined medium for human mesenchymal stem cells | 362 |
| 8 | US6458589B1 | Hepatocyte lineage cells derived from pluripotent stem cells | 360 |
| 9 | EP0481791A2 | Culture medium for CHO-cells and adapted CHO-cells | 357 |
| 10 | WO1998008934A1 | Serum-free mammalian cell culture medium, and uses thereof | 332 |
Citation counts reflect influence within the searched corpus and skew toward older filings; they are not a measure of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data tells you
Read together, the filing trend, the assignee concentration and the IPC spread point to a field that is well-established in its core biology but still open in its process engineering.
Leadership is concentrated but shallow
The leading assignee holds 223 records; fifth place holds 71. The gap between first and fifth is wide enough that a single company's strategy shift can move the ranking, but the top 10 combined still account for only 36.7% of all records — most of the field sits with the long tail.
Volume has cooled off its 2018 peak
Filings peaked at 105 in 2018 and have since fallen to 45 by 2024. That is a real three-year decline, not an artifact of publication lag, since 2024 is the most recent year in this dataset that can be treated as complete.
The field is anchored in cell engineering
Almost all records touch C12N, the microorganism and genetic-engineering class. Fermentation (C12P, 32.5%) and protein chemistry (C07K, 31.9%) are the next-heaviest classes, while bioreactor hardware (C12M, 14.7%) trails well behind the biology.
Filing is US- and Europe-led with a PCT bridge
The United States leads receiving offices at 583 records, followed by the EPO at 472 and WIPO's PCT route at 283. Australia, Israel and Canada each carry over 180 records, indicating routine multi-jurisdiction filing rather than single-market protection.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to mammalian cell culture seed expansion, with the prior art for and against each one.
Assignee landscape
The ranked leaders span large biologics manufacturers, a licensing-focused technology transfer office, and several names now folded into larger portfolios through acquisition. Recent-year momentum for the top names is flat or down, consistent with the field-wide filing decline.
A single company sets the pace
The top-ranked assignee holds 223 records, more than triple the fifth-place count of 71. That gap reflects a long-running, well-resourced filing program rather than a recent surge — recent-year momentum for this name has fallen to zero filings in the latest year.
Most activity sits outside the ranked leaders
With the top 10 combined holding 36.7% of all 2,644 records, the majority of filings belong to assignees outside the ranked leaders — a sign that seed expansion process claims remain accessible to smaller entrants and specialty CROs.
Even active leaders have slowed sharply
Recent-year momentum among the top-ranked assignees is uniformly negative: the most active recent filer dropped 86% year over year to a single filing, and several established names recorded zero filings in the latest year, down 100% YoY.
| Assignee | Recent year | YoY |
|---|---|---|
| Regeneron Pharmaceuticals | 1 | -86% |
| Royal Netherlands Academy of Arts and Sciences | 1 | — |
| Genentech, Inc. | 0 | -100% |
| Technion Research & Development Foundation Ltd. | 0 | — |
| Life Technologies Corporation | 0 | -100% |
| Amgen Inc. | 0 | -100% |
| Wyeth LLC | 0 | — |
| Genzyme Corporation | 0 | — |
Where to take this analysis
The landscape points to specific next steps depending on whether you are clearing a filing, scouting a licensing target, or mapping competitive risk.
Check freedom to operate before filing
Seed expansion's core biology is densely claimed under C12N, but bioreactor integration and analytics classes carry lighter density — run a focused search there before assuming clearance.
Explore in EurekaTrack the leaders' recent pullback
The field-wide decline from 2021 to 2024 shows up in individual assignee momentum too. Watch whether filings recover once 2025-2026 publications catch up, or whether the pullback is structural.
Monitor assignees in EurekaMap co-assignee networks for licensing targets
Co-assignee pairs in this dataset cluster around individual inventors tied to a single leading company, suggesting concentrated internal R&D teams rather than broad external collaboration.
Trace networks in EurekaCommon questions on this landscape
This landscape identifies 2,644 published records filed against seeding density, passage number, viability threshold, doubling time, inoculum train and culture transition concepts within mammalian, animal and CHO cell culture, classified under C12N, C12M and C12Q. The count spans 2015 through the 2026-07-31 data cut-off. Because publication lags filing by roughly 18 months, the most recent one to two years are undercounted and will rise as those applications publish.
The ranked leaders include large biologics manufacturers and a university technology transfer office, with the top-ranked assignee holding 223 records against a fifth-place count of 71. The top 5 assignees combined account for 24.6% of all 2,644 records in scope, and the top 10 account for 36.7%. Most of the field's activity, however, sits with a long tail of assignees outside that ranked group.
Filing activity peaked at 105 records in 2018 and has since declined, falling from 79 in 2021 to 45 in 2024 — a 43% drop over that three-year span. 2024 is the most recent year in this dataset that can be treated as complete; 2025 and 2026 figures will increase as publications catch up. Treat any apparent drop in the very latest years as a lag artifact rather than a real trend.
US8663945B2, assigned to AbbVie Inc. and published 2014-03-04, covers improved methods and compositions for producing a recombinant protein such as an antibody in mammalian cell culture, including improved production media, feed solutions and combination feeds aimed at improving protein productivity. It is a representative filing in this landscape rather than the single most-cited one. Anyone developing feed or media strategies for antibody production in mammalian cell culture should review its specific claim scope directly rather than relying on the abstract alone.
The IPC composition shows core cell-engineering claims under C12N covering 97.3% of records, while process-engineering classes trail well behind — C12M bioreactor and apparatus claims sit at 14.7% and G01N analytical-method claims at 14.4% of records. That gap suggests automated viability sensing, inoculum train scale-down modelling, and bioreactor-integrated doubling-time monitoring are less densely claimed than the underlying cell biology. A freedom-to-operate search focused on those process branches is likely to turn up fewer blocking references than a search on the core biology.
Research Mammalian Cell Culture Seed Expansion in depth with Eureka
Go past this page: query the whole mammalian cell culture seed expansion corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.